phospho-aspirin

Phospho-aspirin (MDC-22) is a **novel modified aspirin derivative** designed to improve efficacy and reduce gastrointestinal toxicity compared to standard aspirin. It consists of aspirin chemically modified by the addition of a phospho group, intended to enhance its anticancer and anti-inflammatory properties while minimizing adverse effects such as gastric ulceration. Mechanistically, phospho-aspirin retains the classic aspirin action of **irreversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2)** and suppression of **prostaglandin and thromboxane synthesis**, but it also demonstrates increased ability to induce apoptosis and inhibit cell proliferation in cancer models. Early-stage studies suggest its primary indication may be for **cancer chemoprevention and therapy** (especially colon and pancreatic cancers), although inflammatory and cardiovascular applications may also be possible. It is not yet approved for clinical use, and is under preclinical and early clinical development.

Other names

phospho-aspirinMDC-22MDC22MDC 22aspirin derivative